**Abstract:** Dominant optic atrophy (DOA), mainly caused by pathogenic variants in *OPA1*, is one of the most common forms of hereditary optic neuropathy. *OPA1* is involved in mitochondrial dynamics and oxidative phosphorylation, among other functions. Hence, mutations in this gene cause the degeneration of retinal ganglion cells (RGCs), leading to reduced visual acuity. In this work, we have used induced pluripotent stem cell (iPSC) technology to generate RGCs, starting from an iPSC line created from fibroblasts from a DOA patient and also its CRISPR isogenic control. The generated RGCs showed expression of BRN3A, SNCG or THY1, and could potentially serve as a platform for DOA modeling.

**Keywords:** dominant optic atrophy; DOA; optic neuropathy; *OPA1*; induced pluripotent stem cells; iPSCs; mitochondria; retinal ganglion cells; CRISPR/Cas9; disease model

**1. Introduction**

Dominant optic atrophy or DOA is a rare progressive disease and one of the most common forms of hereditary optic neuropathy [1]. This condition is mainly triggered by pathogenic variants in the nuclear gene, *OPA1*, which encodes a dynamic-related protein localized in the mitochondrial inner membrane [2,3]. Among other functions, *OPA1* plays a key role in mitochondrial dynamics, cell survival, oxidative phosphorylation and the maintenance of mitochondrial DNA (mtDNA). Mutations in this gene cause a decrease in energy production capacity, leading to the degeneration of retinal ganglion cells (RGCs) and their axons [4]. This implies optic nerve atrophy and reduced visual acuity, leading to legal blindness in many cases. DOA can also be syndromic with extra-ocular features like ataxia, myopathy, chronic ophthalmoplegia and sensorineural deafness, condition known as DOA ‘plus’ [5]. Currently, there is no effective treatment for DOA, due in part to the lack of an appropriate disease model.

The discovery of induced pluripotent stem cells (iPSCs) in 2006 by Sinya Yamanaka started a revolution in biomedical research [6,7]. iPSCs can be generated by reprogramming somatic cells only through the ectopic expression of four transcription factors (OCT3/4, SOX2, KLF4 and C-MYC). The resulting cells present similar molecular and functional characteristics as embryonic stem cells, enabling their directed differentiation into any cell type, such as RGCs.

In recent years, researchers have made great improvements in CRISPR/Cas9 editing techniques. Using a specific RNA guide in combination with Cas9, the correction of any mutation turns out to be feasible, enabling the generation of isogenic iPSC controls [8]. Indeed, patient-derived iPSCs and their related isogenic controls would potentially be differentiated into the target cell type to search for the pathophysiological mechanisms of the disease.
The main objective of this work has been the use of induced pluripotent stem cell (iPSC) technology as a tool for the generation of patient-specific, iPSC-derived RGCs, the affected target cell type in patients with DOA. For that purpose, we have used an iPSC line previously created by reprogramming fibroblasts carrying the pathogenic variant c.1861C>T; p.Q621* in the OPA1 gene. Moreover, our aim has been to correct the causative mutation in OPA1 using a CRISPR/Cas9 tool, and to differentiate both iPSC lines, the mutant and the corrected one, into RGCs. These generated RGCs would enable the precise modeling of DOA, opening up the possibility of identifying an appropriate treatment.

2. Generation of the Isogenic Control Using CRISPR/Cas9 System

In this work, we have used an iPSC line, previously created in our laboratory, from fibroblasts obtained from a DOA ‘plus’ patient carrying the pathogenic variant, c.1861C>T; p.Q621* in the OPA1 gene [9]. Using the CRISPR/Cas9 genome editing tool, this variant in the OPA1 gene has been corrected in the patient-derived iPSCs.

For that purpose, ribonucleoprotein complexes including synthetic guide RNAs have been employed, in combination with a single-stranded DNA oligonucleotide template [10]. Following this protocol, 96 clones were manually isolated and, after Restriction Fragment Length Polymorphism (RFLP) analysis, 15.25% edition efficiency has been obtained. Then, the clones that were found to be positive in the analyses were sequenced by Sanger for confirmation.

One of these clones has been selected based on morphological and growth criteria. Subsequently, a complete battery of tests was performed in order to confirm the pluripotency and integrity of the edited line. The iPSC line showed expression of pluripotency markers, such as SOX2, OCT4, NANOG or C-MYC, which was verified by immunocitochemistry and real-time PCR. It was possible to generate the three germ layers, endoderm, mesoderm and ectoderm (as shown by α-fetoprotein, β-III-tubulin and smooth muscle actin expression). Using DNA fingerprinting analysis, we determined that the line had the same origin as the previously reported iPSCs [9]. The line was also mycoplasma-negative and exhibited a normal karyotype.

3. iPSC Differentiation Towards an RGC Lineage

We have differentiated both DOA iPSCs and the corrected iPSCs into RGCs using an stepwise protocol [11]. It consisted of the addition of several small molecules to activate and repress different pathways in order to mimic embryonic development. For this purpose, embryoid bodies were generated in suspension, being transferred to Matrigel for the formation of neural rosettes. Afterwards, retinal progenitor cells were isolated from these structures and further differentiated to RGCs in poly-D-lysine and laminin.

The generated RGCs showed expression of typical RGC markers, such as BRN3A, SNCG or THY1, both in immunocytochemistry and RT-PCR.

4. Conclusions and Future Perspectives

In this study, an isogenic RGC model of DOA ‘plus’ disease has been successfully generated. This model will be very useful in understanding the pathophysiological mechanisms underlying DOA, as well as a platform to search for a potential treatment.

Author Contributions: Conceptualization, M.E.G.; methodology, M.G.-L.; resources, M.E.G.; writing—original draft preparation, M.G.-L.; writing—review and editing, M.E.G.; supervision, M.E.G.; project administration, M.E.G.; funding acquisition, M.E.G. All authors have read and agreed to the published version of the manuscript.

Funding: This work has been funded by grants from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (ISCIII): PI15/00484, CPI16/00046 and PI18/00151 to MEG (co-funded by European Regional Development Fund “A way to make Europe”); PI21/00162 and CPI21/00011 co-funded by the European Union to MEG; Organización Nacional de Ciegos Españoles (ONCE) to M.E.G. M.G.-L. receives grant support from a PFIS grant (FI19/00043) from the Instituto de Salud Carlos III and the European Regional Development Funds (ERDF).
Institutional Review Board Statement: The study was approved by the Ethics Committee of the ‘Hospital Universitario 12 de Octubre’ (Madrid, Spain) (protocol 21/482) and was performed in accordance with the Declaration of Helsinki for Human Research.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Data are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.